Latest Production Development News

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.

BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.

Micro-X Limited's trading suspension has been lifted following its announcement of an equity raising, signaling renewed market activity for the medical technology firm.

Micro-X has raised $3.3 million through a placement and institutional entitlement offer, reinforcing its strategic shift towards medical imaging technologies. A retail entitlement offer aiming to raise an additional $2.7 million will open shortly, supporting the company’s development of mobile X-ray and CT products.

MyEco Group Ltd is advancing its transformation into a global leader in sustainable packaging, refining its sales and production strategies to drive growth and achieve positive EBITDA.

Vection Technologies has elevated its market position by achieving Dell Technologies' highest partner tier, following a $4 million defence contract extension that underpins its growth in AI and XR solutions.

Acrux Limited announces the retirement of CEO Michael Kotsanis after more than 10 years at the helm, with a search underway for his successor to lead the next phase of growth.

Spacetalk Ltd has secured a $428,853 R&D tax rebate from the Australian Taxation Office, reinforcing its commitment to innovation while reporting a 16% increase in Annual Recurring Revenue and significant cost reductions.

Micro-X Ltd has announced a $6 million capital raising alongside a $2.4 million strategic investment from Billion Prima, underpinning its pivot towards medical imaging and cashflow stability.

WA Kaolin Limited is raising A$7 million through a fully underwritten entitlement offer to support its sales ramp-up and working capital needs, following a successful upgrade to its classifier project that enhances production capabilities.

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.